Drug Screening Market worth USD 10.0 billion by 2025 - Leading Companies are LabCorp (US), Quest Diagnostics (US), Alere (US), OraSure (US), Alfa Scientific Designs (US), LifeLoc (US), Omega Laboratories (US), Premier Biotech (US)

According to the new market research report "Drug Screening Market by Product (Consumables, Urine testing devices, Analytical, Breathalyzer, Chromatography) & Services, Sample Type (Urine, Breath), End User (Workplace, Laboratories, Criminal Justice, Hospitals) - Global Forecast to 2025", published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints/challenges, and opportunities in North America, Europe, Asia Pacific, and the Rest of the World.

The Drug Screening Market is projected to reach USD 10.0 billion by 2025 from USD 4.5 billion in 2020, at a CAGR of 17.3% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162987773#utm_source=Openpr&utm_medium=paidpr

The rising drug & alcohol consumption, the enforcement of stringent laws mandating drug and alcohol testing, government funding in major markets, and regulatory approvals and product and service launches are the major factors driving the growth of this market.

Services segment expected to grow at the highest CAGR during the forecast period.

Based on service and product, the drug screening market is segmented into services and products. Services segment accounted for the largest share of the market in 2019. This segment is also expected to register the highest CAGR during the forecast period, mainly due to the growing drug and alcohol consumption worldwide, funding initiatives for drug testing laboratories, new service launches, and regulatory approvals, and geographic expansion of drug and alcohol testing laboratories.

Browse in-depth TOC on "Drug Screening Market"
192 – Tables
35 – Figures
192 – Pages
Get 10% Customization on this Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=162987773#utm_source=Openpr&utm_medium=paidpr

Analytical instruments are expected to dominate the drug screening products market in 2019.

Based on the product, the drug screening market is segmented into analytical instruments, rapid testing devices, and consumables. In 2019, the analytical segment is expected to dominate the market. Growing alcohol consumption and drunken driving cases, stringent government laws mandating drug and alcohol testing, and technological advancements in this market are some of the key factors driving the growth of the analytical instruments market.

Based on the sample type, the oral fluid segment is projected to grow at the highest CAGR during the forecast period.

By sample type, drug screening market is segmented into urine, breath, oral fluid, hair, and other samples. Among these, the oral fluid segment is expected to register the highest CAGR during the forecast period. The high growth of this segment is attributed to the increasing preference for oral fluid samples because of the convenient collection method, no specific requirement for sample collection, and low risk of sample adulteration.

North America to dominate the drug screening market in 2019

In 2019, North America is expected to dominate the market, followed by Europe. The large share of this geographical segment is attributed to factors such as growing consumption of illicit drugs, the availability of government funding to curb drug addiction, the presence of laws supporting drug screening, and the growing burden of road accidents due to alcohol consumption in the region.

Request for Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=162987773#utm_source=Openpr&utm_medium=paidpr

Key Players

The market is highly competitive with the presence of several small and big players. Some of the players offering products for drug screening market LabCorp (US), Quest Diagnostics (US), Alere (US), OraSure (US), Alfa Scientific Designs (US), Thermo Fisher Scientific (US), Drägerwerk (Germany), LifeLoc (US), MPD Inc. (US), Omega Laboratories (US), Premier Biotech (US), Psychemedics (US), Roche (Switzerland), Shimadzu (Japan), Siemens Healthineers (Germany), American Bio Medica Corporation (US), Sciteck, Inc. (US), ACM Global Laboratories (US), CareHealth America (US), and Clinical Reference Laboratory (US).

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

About MarketsandMarkets
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth emerging opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's™ flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

This release was published on openPR.